Table 2. Prior regimens received by patients.
| Carfilzomib n=157 | Control n=158 | Total N=315 | |
|---|---|---|---|
| Number of prior regimens, n (%) | |||
| Median (range) | 5 (3–15) | 5 (3–17) | 5 (3–17) |
| 3 | 17 (11) | 19 (12) | 36 (11) |
| 4 | 34 (22) | 35 (22) | 69 (22) |
| 5 | 39 (25) | 37 (23) | 76 (24) |
| ⩾6 | 67 (43) | 67 (42) | 134 (43) |
| Median number of unique prior antimyeloma drugs (range) | 8 (5–17) | 8.5 (4–14) | 8 (4–17) |
| Patients who had prior transplant, n (%) | 107 (68) | 102 (65) | 209 (66) |
| Refractory to most recent therapy, n (%) | 157 (100) | 157 (99) | 314 (100) |
| Nonresponsive (<MR) | 112 (71) | 112 (71) | 224 (71) |
| Progression during therapy | 82 (52) | 83 (53) | 165 (52) |
| Progression within 60 days of completion of therapy | 34 (22) | 39 (25) | 73 (23) |
| Prior therapy received, n (%) | |||
| Bortezomib, IMiD, alkylating agent, corticosteroid | 157 (100) | 158 (100) | 315 (100) |
| Lenalidomide | 132 (84) | 125 (79) | 257 (82) |
| Thalidomide | 116 (74) | 124 (78) | 240 (76) |
| Pomalidomide | 12 (8) | 8 (5) | 20 (6) |
| Anthracyclines | 117 (75) | 122 (77) | 239 (76) |
| Received in last prior regimen, n (%) | |||
| Bortezomib | 36 (23) | 41 (26) | 77 (24) |
| Bortezomib refractory in last prior regimen | 36 (23) | 41 (26) | 77 (24) |
| Refractory to (in any prior regimen), n (%) | |||
| Bortezomib | 103 (66) | 108 (68) | 211 (67) |
| Lenalidomide | 114 (73) | 112 (71) | 226 (72) |
| Thalidomide | 84 (54) | 94 (59) | 178 (57) |
| Bortezomib and IMiD | 97 (62) | 100 (63) | 197 (63) |
| Alkylating agents | 136 (87) | 133 (84) | 269 (85) |
Abbreviations: IMiD, immunomodulatory agent; MR, minimal response.
Patients may be counted in more than one category.